Related Experiment Video

Updated: Oct 23, 2025

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

10.3K

Verteporfin suppresses osteosarcoma progression by targeting the Hippo signaling pathway

Xianliang Yang1,2, Youjia Xu1, Chao Jiang2

  • 1Department of Orthopedics, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215004, P.R. China.

Oncology Letters
|August 25, 2021
PubMed

Insights

Verteporfin (VP) effectively inhibits osteosarcoma progression by downregulating YAP1 and TEAD1 expression. This targeted approach suppresses tumor cell viability, migration, and invasion, offering a promising therapeutic strategy for osteosarcoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Osteosarcoma is a primary bone malignancy with limited effective treatments.
  • Yes-associated protein 1 (YAP1) and TEA domain transcription factor 1 (TEAD1) are implicated in tumor progression.
  • Verteporfin (VP) is a known inhibitor of YAP1 signaling.

Purpose of the Study:

  • To investigate the inhibitory effects of Verteporfin (VP) on osteosarcoma.
  • To elucidate the underlying molecular mechanisms of VP's anticancer activity in osteosarcoma.
  • To evaluate the therapeutic potential of VP against osteosarcoma progression.

Main Methods:

  • Cell viability, cell cycle, apoptosis, migration, and invasion assays were performed.
  • Gene and protein expression levels of YAP1, TEAD1, and CYR61 were analyzed.
  • Co-immunoprecipitation identified YAP1 and TEAD1 interactions.
  • In vivo mouse xenograft models assessed tumor growth inhibition.

Main Results:

  • YAP1 and TEAD1 were highly expressed in osteosarcoma.
  • VP significantly downregulated YAP1 and TEAD1 expression in Saos-2 cells.
  • VP suppressed osteosarcoma cell viability, migration, invasion, and induced apoptosis and G1 cell cycle arrest.
  • VP inhibited tumor growth in a mouse xenograft model.
  • CYR61 overexpression partially reversed VP's inhibitory effects.

Conclusions:

  • Verteporfin (VP) effectively suppresses osteosarcoma progression by inhibiting YAP1 and TEAD1 expression.
  • VP demonstrates significant anticancer effects on osteosarcoma cells in vitro and in vivo.
  • CYR61 may play a mediating role in VP's therapeutic action against osteosarcoma.
Keywords:
TEA domain transcription factor 1cysteine-rich protein 61osteosarcomatumorigenesisverteporfinyes-associated protein 1

More Related Videos

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor07:16

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor

Published on: September 13, 2018

20.2K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.4K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.2K